Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCLG-AML2019 pediatric AML maintenance study
ChiCTR1900027146Phase 4Recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- Nov 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of cytarabine, tioguanine, tretinoin and Compound Huangdai Tablet in acute myeloid leukemia (AML) (2 arms), sponsored by Beijing Children's Hospital. Primary endpoints: Remission state of bone marrow and Three-year event-free survival. Started Nov 2019; status: recruiting.
02
Drugs
cytarabinetioguaninetretinoinCompound Huangdai Tablet
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR1900027146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027146.